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INTRODUCTION
Preoperative chemotherapy has been used for the treatment 
of breast cancer since the 1970s, with Lyall et al. [1] being the 
first to apply neoadjuvant chemotherapy to the treatment of 
unresectable, locally advanced breast cancer. More recently, a 
study evaluated the use of curative resection following the ad-
ministration of neoadjuvant chemotherapy for patients diag-
nosed with unresectable breast cancer [2]. However, in some 
cases, the efficacy of neoadjuvant chemotherapy was not suffi-
cient to prevent tumor progression, and the delay associated 
with surgery was found to adversely affect a patient’s condi-
tion [3]. 
In 1981, criteria were established that standardized the pre-
diction of tumor invasion for therapeutic evaluations. These 
criteria have subsequently been modified by various cancer 
organizations including the World Health Organization (WHO), 
the National Cancer Institute, and the European Organization 
for Research and Treatment of Cancer [4]. Accordingly, a new 
set of tumor response criteria have been established, and are 
referred to as the Response Evaluation Criteria in Solid Tumours 
(RECIST) [5]. However, RECIST does not provide guidelines 
for the assessment of lesions classified as non-measurable le-
sions. Moreover, imaging studies have demonstrated that tu-
mor images obtained can misrepresent the extent of present 
tumor [6]. Hence, the efficacy of the current RECIST in deter-
mining the extent of tumor invasion needs to act as re-evalu-
ated. Correspondingly, the goal of this study was to investigate 
the capacity for cancer stem cells to be a readout for tumor in-
vasion. 
Previous studies have confirmed that tumor stem cells play 
an important role in tumor recurrence, metastasis, and chemo- 
therapy resistance for various types of tumors, including 
breast cancers [7,8]. For example, in 2003, Al-Hajj et al. [7] in-
dentified a small population of breast cancer stem cells within 
a breast tumor that were associated with tumor maintenance 
of the tumor. In addition, breast cancer stem cells have been 
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Purpose: To investigate the distribution of CD44
+/CD24
- cells in 
breast cancers in relation to tumor size before and after the ad-
ministration of neoadjuvant chemotherapy. Methods: CD44
+/
CD24
- tumor cells obtained from breast cancer specimens were 
characterized in vivo and in vitro using tumor formation assays 
and mammosphere generation assays, respectively. The distri-
bution of CD44+/CD24- tumor cells in 78 breast cancer speci-
mens following administration of neoadjuvant chemotherapy was 
also evaluated using immunofluorescence assays, and this distri-
bution was compared with the extent of tumor invasion predict-
ed by Response Evaluation Criteria in Solid Tumours (RECIST). 
Results: In 27/78 cases, complete remission (CR) was identified 
using RECIST. However, 18 of these CR cases were associated 
with a scattered distribution of tumor stem cells in the outline of the 
original tumor prior to neoadjuvant chemotherapy. After neoadju-
vant chemotherapy, 24 cases involved cancer cells that were con-
fined to the tumor outline, and 21 cases had tumor cells or tumor 
stem cells overlapping the tumor outline. In addition, there were 6 
patients who were insensitive to chemotherapy, and in these cases, 
both cancer cells and stem cells were detected outside the con-
tours of the tumor volume imaged prior to chemotherapy. Con-
clusion: CD44+/CD24- tumor cells may be an additional param-
eter to evaluate when determining the extent of breast cancer in-
vasion. 
Key Words: Breast neoplasms, Neoadjuvant chemotherapy, Neoplasm invasion, 
Stem cells
Correspondence:  Shaokun Zhang
The First Bethune Hospital of Jilin University, Changchun, Jilin 130021, China
Tel: +86-15940-50-2858, Fax: +86-024-8328-2618
E-mail: angel-s205@163.com
This study was funded by the China National Natural Science Foundation 
(No. 30772100).
Received: May 30, 2011  Accepted: September 9, 2011
Journal of
        Breast
Cancer176  HongWu,etal.
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2011.14.3.175
shown to disseminate from a primary breast tumor and estab-
lish secondary tumors in distant organs such as the brain, liver, 
and lungs [7,8]. However, it remains unclear whether the biol-
ogy or distribution of breast cancer stem cells is affected by neo-
adjuvant chemotherapy. It also remains unclear whether stem 
cells exist outside of a tumor according to the current criteria. 
Currently, the distribution status of tumor stem cells before 
and after neoadjuvant chemotherapy remains controversial, as 
well as how this distribution relates to tumor size [9]. There-
fore, the objective of this study was to investigate the popula-
tion of CD44
+/CD24
- tumor cells present in primary breast 
cancers, and to predict the extent of tumor invasion based on 
this subset of cells using RECIST. 
METHODS
Patients and tissue specimens
A total of 78 patients with histologically confirmed breast 
cancer underwent radical operations following neoadjuvant 
chemotherapy at The First Affiliated Hospital of Bethune Med-
ical College, The First Hospital of the China Medical Univer-
sity and Liaoning Province Tumor Hospital between January 
2007 and January 2011. The inclusion criteria were as follows: 
1) curative operations were performed; 2) resected specimens 
were pathologically examined; 3) more than 15 lymph nodes 
were pathologically examined following an operation; and 4) 
a complete medical record was available. 
The study protocol was approved by the Ethics Committee 
of The First Affiliated Hospital of Bethune Medical College, 
The First Hospital of the three Hospitals and Liaoning Province 
Tumor Hospital.
Experimental materials
For flow cytometry analyses, fluorescence conjugated anti-
bodies including: CD24-PE, CD44-FITC, CD2-FITC, CD3-
APC, CD10-PE, CD16-FITC, CD18-APC, CD31-PE, and 
CD326-FITC (EpCAM) were used for FACS selection and were 
obtained from BD Pharmingen (San Diego, USA). Ultra-low 
adherent plates, sterile cell scrapers, MammoCult Basal Medi-
um, MammoCult Proliferation Supplement, Hank’s buffered 
salt solution (HBSS), hydrocortisone, and heparin were also 
purchased from Stem Cell Technologies (Vancouver, Canada). 
Tumor formation assay
Human mammary tissue (1×1×1 cm
3 per specimen) was 
minced into 1×1×1 mm
3 pieces with scalpels, washed three 
times with PBS, and transferred to tissue dissociation flasks. 
Tissue pieces were incubated with collagenase III at 37°C and 
mixed using a 10-mL pipette every 15-20 minutes. After 3-4 
hours, cells were filtered through a 45-μm nylon mesh and 
washed twice with PBS. Staining with trypan blue was used to 
count viable cells and to remove dead cells. 
Flow cytometry was performed using a FACSVantage (FAC-
SCALIBUR; BD Pharmingen). Cells were routinely sorted twice, 
then reanalyzed for purity, which typically was >95%. Briefly, 
cells positive for CD2, CD3, CD10, CD16, CD18, CD31, and 
CD326 were initially sorted out using flow cytometry. Dead 
cells were also eliminated according to staining detected with 
the viability dye, 7AAD. Subsequently, CD44+/CD24- tumor 
cells were selected, combined with RPMI-1640 medium and 
Matrigel (1:1 volume) and injected into the appropriate area 
of the mammary fat pad. 
Mammosphere generation assay
Complete MammoCult
TM Medium (human) was supple-
mented with MammoCult
TM Proliferation Supplements (hu-
man) and then added to MammoCult
TM Basal Medium (Hu-
man). Cells were suspended in this prepared media before be-
ing plated on ultra-low attachment plates (Corning, USA) at a 
density of 2×10
4 viable cells/mL. The number of spheres that 
developed in each well was counted after 7 days.
Immunofluorescence assays
Specimens (0.5×0.5×0.5 cm
3) were resected at 1 cm inter-
vals from the tumor diameter up to 3 cm outside the maximum 
diameter of the tumor. Briefly, breast cancer tissues and non-
neoplastic breast tissues were prepared as paraffin blocks. Sec-
tions were cut (4 μm) and deparaffinized in xylene (2×, 5 min-
utes each), hydrated with 100% ethanol (2×, 3 minutes each), 
and incubated in 95% ethanol for 1 minute. Sections were then 
rinsed in distilled water and fixed in 3-4% paraformaldehyde 
in PBS (pH 7.4) for 15 minutes at RT. Samples were washed 
twice with ice-cold PBS and then incubated with PBS contain-
ing 0.25% Triton X-100 for 10 minutes. After three washes in 
PBS, samples were incubated with 1% bovine serum albumin 
(BSA) in PBS-Tween for 30 minutes to block non-specific bind-
ing. Sections were then incubated with rabbit anti-human CD44 
and mouse anti-human CD24 antibodies in 1% BSA/PBS-Tween 
in a humidified chamber for 1 hour at RT, or overnight at 4°C. 
After three washes with PBS, sections were incubated with FITC-
conjugated anti-rabbit and APC-conjugated anti–mouse anti-
bodies in 1% BSA for 1 hour at RT in the dark. Sections were 
subsequently incubated with 0.1-1 μg/mL Hoechst or DAPI 
for 1 minute to stain for DNA. After adding a drop of mount-
ing medium, sections were mounted with coverslips and sealed 
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RESULTS
Characterization of CD44
+/CD24
- tumor cells 
CD44
+/CD24
-, CD44
+/CD24
+, and CD44
- cell subsets were 
isolated from the tumor specimens collected using flow cyto- 
metry. CD44
+/CD24
- cells have previously been identified as 
breast cancer stem cells [7,10], and therefore, were combined 
with Matrigel to be injected into the mammary fat pad of NOD/ 
SCID mice. After 20 days, tumors were detected in 3/5 mice 
(Figure 1). In contrast, tumors only formed in 1/5 mice which 
had been injected with 1×10
6 control cells (e.g., CD44
+/CD24
+ 
and CD44
- cells) combined with Matrigel, compared to 5×10
3 
CD44
+/CD24
- cells combined with Matrigel. Furthermore, 
CD44
+/CD24
- cells were observed to form mammospheres 
one week after being cultured in serum-free medium, while 
control cells did not (Figure 2).
Figure 1. CD44
+/CD24
- cells (5×10
3) were combined with Matrigel 
and injected into the mammary fat pad of NOD/SCID mice. An example 
of a successfully established solid tumor is indicated with an arrow.
Figure 2. CD44
+/CD24
- cells were observed to form mammospheres one week after being cultured in serum-free medium (A: ×20), while control 
cells did not (B: ×20).
A B
Figure 3. Various distributions of stem cells were observed following the administration of neoadjuvant chemotherapy. For example, few CD44+/CD24- 
tumor cells were observed in specimens from case no. 17 (A: ×10), while CD44+/CD24- tumor cells were observed to be distributed at the edge of 
the tumor in case no. 4 (B: ×10). Staining was performed with: mouse anti-human CD44 antibody and APC conjugated secondary (1); rabbit anti-hu-
man CD24 antibody with FITC conjugated secondary (2), and DAPI for the detection of nuclei (3). An overlay of panels (1), (2), and (3) is presented in (4).
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The relationship between tumor stem cell distribution and 
tumor outlines
When the distribution of CD44+/CD24- tumor cells deter-
mined from clinical examinations and radiological evaluations 
performed prior to the administration of neoadjuvant chemo-
therapy were compared with immunofluorescence studies per-
formed on tissue sections obtained from surgical resection of 
tumors following neoadjuvant chemotherapy, differences in 
the localization of CD44+/CD24- tumor cells were observed. 
For example, prior to treatment with neoadjuvant chemother-
apy, CD44+/CD24- tumor cells mainly localized to the edge 
of the breast tumors analyzed: However, following the admin-
istration of neoadjuvant chemotherapy, various distributions 
of CD44+/CD24- tumor cells were observed (Figure 3). For 
each of these patterns described below, a subgroup designation 
has been indicated in parentheses (i.e., Type I), the designations 
representing a proposed tumor invasion classification criteria 
that will be addressed in the Discussion (Figure 4).
Of the 78 cases, 27 were identified as being in complete remis-
sion (CR) according to RECIST. Moreover, of these 27 cases, 9 
did not contain tumor cells (Type I), and 18 cases exhibited a 
scattered distribution of CD44+/CD24- tumor cells in the out-
line of the original tumor identified prior to neoadjuvant chemo- 
therapy (Type II). Another 24 cases were associated with a distri-
bution of cancer cells confined within the tumor outline iden-
tified following chemotherapy (Type III), while another 21 cases 
were associated with CD44+/CD24- tumor cells localized to the 
outline of the tumor following neoadjuvant chemotherapy. In 
the latter 21 cases, 9 involved tumor cells (Type IV) (Figure 5), 
6 had tumor stem cells that also localized to the outline of the 
tumor following neoadjuvant chemotherapy (Type V), and 6 
cases involved tumors that were insensitive to chemotherapy, 
resulting in the extension of cancer cells and stem cells outside 
the tumor outline established prior to chemotherapy (Type VI).
DISCUSSION
Currently, an increasing number of breast cancer patients 
I II III
IV V VI
Figure 4. Proposed tumor invasion classification criteria. Turquoise and 
magenta regions represent the tumor size identified before and after 
chemotherapy, respectively, while the red and blue circles represent the 
distribution of CD44+/CD24- and non-CD44+/CD24- tumor cells, re-
spectively, associated with each type of tumor invasion.
Figure 5. For case no.12, tumor stem cells were observed to localize to the outline of the tumor following neoadjuvant chemotherapy (A: ×10). For 
case no. 25, cancer stem cells were detected in the vascular system of paracancerous tissues (B: ×10) and this was consistent with the results of 
immunofluorescence assays.
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are requesting that as much breast tissue as possible be main-
tained following a diagnosis of breast cancer [11]. Hence, the 
efficacy of the evaluation criteria used to determine the extent 
of tumor invasion has become very important in order to en-
sure the safety of the surgery, and to optimize the prevention 
of tumor recurrence. The decision to administer neoadjuvant 
chemotherapy for the treatment of breast cancer has been based 
on a clinical examination, a radiology evaluation including 
mammography, ultrasound, radionuclide, magnetic resonance 
imaging (MRI), and oxygen functional imaging, as well as pa-
thology studies that include the detection and evaluation of 
molecular markers [12,13]. However, evaluation methods have 
been very limited for cases of breast cancer that involve a con-
servation approach for surgical resection since pathological 
studies cannot be performed for specimens outside conserva-
tively designated surgical margins. Therefore, oncologists have 
had to depend on clinical examinations and radiology evalua-
tion methods to evaluate the extent of existing tumor invasion. 
Therefore, the goal of this study was to evaluate the distribution 
of CD44
+/CD24
- tumor cells (which may represent an enriched 
population of breast cancer stem cells) for 78 cases of modified 
radical mastectomy that were performed following neoadjuvant 
chemotherapy according to the current criteria. To our surprise, 
we observed that some tumor cells, including CD44
+/CD24
- 
cancer stem cells, were scattered outside the tumor scope de-
termined by currently accepted evaluation parameters for neo-
adjuvant chemotherapy.
Based on the results obtained from comparing tumor dis-
tributions prior to and following neoadjuvant chemotherapy, 
six patterns of distribution were identified. These patterns were 
labeled in the Results section, and represent a new tumor in-
vasion classification system we propose based on the present 
study. 
The proposed types include Type I and II, which relate to 
breast cancers considered to be in CR according to RECIST. 
Moreover, although Type II and imaging do not touch the body 
mass, there are foci there exhibited scattered tumor stem cells 
after chemotherapy. Types III- V were considered to represent 
tumors that exhibited a partial response (PR) to chemother- 
apy, or a stable disease (SD). In addition, Type III accurately 
reflected the extent of the tumor after chemotherapy. However, 
Type IV and Type V cases involved the presence of tumor cells 
outside the smaller tumor achieved following chemotherapy, 
especially in Type V cases. Furthermore, the distribution of 
stem cells in these cases also extended outside the currently 
accepted standard observable tumor invasion range. Overall, 
it is proposed that breast-conserving surgery is very danger-
ous for Type II and Type V breast cancer cases if tumor inva-
sion is not carefully evaluated. 
Usually, tumor resection surgeries include the collection of 
tissue specimens from the margin of the tumor resected, which 
are subsequently sent for pathological examinations to deter-
mine whether any residual tumor cells remain. However, ac-
cumulating evidence has indicated that these collected speci-
mens do not accurately reflect the actual distribution of cancer 
cells. For example, neoadjuvant chemotherapy may reduce the 
overall tumor volume; however, residual tumor cells can still 
exist outside of the shrunken tumor, and just outside the sur-
gical margin. Secondly, breast tumor cells have the potential to 
migrate to the duct, which was an aspect not fully considered 
in the present study. In contrast, the capacity for tumor stem 
cells to be insensitive to chemotherapy, radiation, or targeted 
therapy has been considered in the proposed Type II and Type 
V breast cancers, where local recurrence was associated with 
incomplete breast resections and residual tumor stem cells that 
remained.
In the past decade, the breast cancer stem cell theory has 
gradually been accepted by most oncologists [7,14]; however, 
research of breast cancer stem cells has come under unprece-
dented pressure to establish a stable breast cancer stem cell line 
in order to study the mechanisms involved. Research on breast 
cancer stem cells would be further improved by including con-
siderations of disease control and treatment [15]. Although our 
study proposed clinical classifications for characteristics asso-
ciated with tumor cell biology, the translation of these results 
into the clinic is limited by the relatively small number of cases 
and the short follow-up associated with each case evaluated. 
In addition, the determination of margins between breast can-
cer tissues and non-neoplastic breast tissues was made accord-
ing to visual inspection during surgery due to technical limi-
tations. Therefore, a larger number of breast cancer cases need 
to be analyzed, and need to include longer follow-up studies, 
in order to confirm the results of this study. 
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